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Background: Lysosomal storage disease (LSD) is a rare inherited disease group. Consecutively there are few data
on cardiac changes in mucopolysaccharidosis (MPS), Anderson Fabry disease (AFD), and other LSD (oLSD)
including Pompe disease (PD) and Danon disease (DD), I-cell disease ICD and mucolipidosis III (ML III).
Methods: Between 1994 and 2011, we identiﬁed 39 patientswith LSD: 25withMPS, 8 with AFD, and 6with oLSD
including PD (1), ML III (2), DD (1), and ICD (2) at our institution fulﬁlling the inclusion criteria of at least one
echocardiogram and ECG.
Results: Median age was 11.4 years (range: 2–27), 22 were females (56%). Normal echocardiograms were
present in 12 patients (31%): 4 with MPS (16%), 7 AFD (88%), and 1 oLSD (17%). Valvular heart disease was
present in 23 patients (59%) occurring more often in MPS (76%) and oLSD (67%) than in AFD (0%) (p b 0.001).
Themost common ECG abnormalitywas a short PR interval in 10 of 35 patients (29%) occurring in all LSD groups.
Median follow-up was 5.8 (0.2–22.2) years showing diminished 5-year survival compared to an age-matched
group. However, no patient died due to a cardiac cause and no cardiovascular intervention was necessary.
Conclusion: Echocardiographically detectable cardiovascular involvement in childrenwith LSD ismostly conﬁned
toMPS and oLSD. Valve thickening in echo and a short PR interval in the ECG are themost frequent abnormalities.
Routine repeat assessment is recommended in LSD. However, signiﬁcant cardiac disease necessitating cardiac
intervention is rare during a short follow-up.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Lysosomal storage disease (LSD) is a heterogeneous group of more
than 40 different disorders due to genetic defects in a lysosomal acid
hydrolase, causing progressive lysosomal accumulation of substrates
speciﬁc for each disorder involving multiple organs; the severity of dis-
ease depends on residual enzyme activity. LSD shows an accumulation
of various glycosaminoglycans, glycoproteins, or glycolipids within the
lysosomes of various tissues [1]. LSD can affect the heart and constitute
an important distinct and treatable cause of cardiomyopathy in chil-
dren, accounting for approximately 5% of pediatric cardiomyopathies
[2]. The most common LSDs in children are Anderson–Fabry disease
(AFD),mucopolysaccharidosis (MPS) and Gaucher disease [3]. In adults,
AFD is the most prevalent LSD; cardiac involvement in AFD in adults
can mimic hypertrophic cardiomyopathy [4]. In MPS pronounced
cardiovascular involvement can be a cause of death apart from upperChildren's University Hospital,
er).
land Ltd. Open access under CC BY-NCairway obstruction [5–7]. There are only rare studies comparing cardiac
involvement between the various types of LSD. Most of these studies
focus on one large group of the disorders such as MPS [7].
The aim of this study was ﬁrst to describe and compare echocardio-
graphic ﬁndings of clinical symptoms and ECG in children with LSD in a
single institution, and second to analyze the possible impact of cardiac
disease on survival.
2. Methods
2.1. Patients
The echocardiography database of the Children's University Hospital Zurich was
searched from January 1994 to April 30, 2011. All patients with a diagnosis of MPS, AFD,
mucolipidosis II and III (ML), Pompe disease (PD), or Danon (DD) disease were reviewed
to meet our inclusion criteria of a biochemical or genetic diagnosis of the respective LSD. If
the patient had more than one echocardiographic exam, the last exam was analyzed.
To segregate possible differences the study population was divided into 3 groups:
MPS, AFD and other LSD group consisting of DD, PD and ML patients (oLSD). There were
40 patients fulﬁlling the inclusion criteria; as one patient refuses any research participa-
tion, 39 patients were included in the study. The local ethical committee approved the
study according to institutional requirements.-ND license.
Table 2
Detailed summary of all our patients with the different LSD.
Group Diagnosis No. pts Age at most recent echo (years)
MPS MPS I: Hurler 7 2, 2, 4, 6, 10, 11, 13
MPS I: Scheie 1 16
MPS II: Hunter 4 13, 15, 16, 19
MPS IIIa/b 4 7, 11, 16, 19
MPS IVa 6 3, 9, 11, 11, 12, 13
MPS VI 2 9, 10, 17
Total 25
AFD AFD 8 6, 7, 8, 10, 11, 13, 13, 17
oLSD Pompe disease (PD) 1 4
Danon disease (DD) 1 15
ML II: I-cell disease (ICD) 2 2, 4
ML III 2 12, 27
Total 6
MPS = mucopolysaccharidosis; AFD = Anderson Fabry disease; ML = mucolipidosis;
PD = Pompe disease; DD = Danon disease; ICD = I-cell disease.
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A complete two-dimensional and Doppler echocardiographic examwas performed in
each patient according to the criteria of the American Society of Echocardiography [8,9].
Left ventricular (LV) ejection fraction was determined using biplane Simpson's method.
Left ventricular hypertrophy was deﬁned as the Z-score of the left ventricular mass
index (LVMI) being N+2 standard deviations (SD) [10]. Dilatation of the LV or left atrium
(LA) was deﬁned as a Z-score N +2SD [8,9]. BSA was calculated using the Mosteller for-
mula [11]. Diastolic function was evaluated and analyzed as previously described includ-
ing left ventricular inﬂow pattern, Doppler tissue imaging (including the E/e′ ratio), the
isovolumic relaxation time and the pulmonary venous ﬂow reversal velocity [12,13].
The severity of valvular regurgitation and stenosis was determined according to ASE-
guidelines [14]. Pulmonary hypertension wasmeasured non-invasively and deﬁned as an
estimated systolic pulmonary artery pressure of N35 mm Hg.
2.3. Electrocardiogram and 24 hour ECG
AnECGwas available for review in 36 patients (92%). All ECGswere analyzed for heart
rate, PR interval, QRSduration,QTc duration,QRS axis, and thepresence of preexcitation or
AV block. A 24-hour ECG was available in 12 patients (31%).
2.4. Follow-up
Follow-up for survival analysiswas obtained in 38 patients (97%) from their last echo-
cardiographic examination until April 30, 2011 by a clinical examination at our institution.
One patientwas lost to follow-up after referral to another center, where his follow-up data
were not further accessible after he reached adulthood.
2.5. Statistical analysis
Categorical variables were compared using chi-square analysis (two-sided exact sig-
niﬁcance). Continuous variables were expressed as mean ± 1 SD or as median with
range and were compared using the Kruskal-Wallis test. All statistical analysis was
two-tailed with a p-value of b0.05 to indicate statistical signiﬁcance. Overall survival
was analyzed using Kaplan–Meier curves using the log-rank test. Expected survival of
an age and sex matched US-population was computed using the R package survival
[15]. Statistical analyses were performed using IBM SPSS Statistics version 20 (SPSS Inc.,
Chicago, IL, USA).
3. Results
A detailed summary of the exact type of LSD, the number of patients
and the age at the echocardiographic exam is shown in Table 2.MPSwas
the most common LSD occurring in 25 patients (64%), whereas 8 pa-
tients (21%, 7 female) had AFD. The remaining 6 patients (15%) had
oLSD. The largest groups among the MPS were MPS I (Hurler disease,
7 patients) and MPS IVa (6 patients).
3.1. Clinical characteristics
Clinical characteristics are shown in Table 3. Therewas no signiﬁcant
difference in median age, median bodyweight and gender between the
3 groups. A heart murmur was present in 49% of patients. Most patients
were in NYHA class I. One patient of the oLSD group (20%) was in NYHA
class III. Signs of heart failure were observed in 3 patients with MPS
(1 with MPS, 2 with MPS VI) and in the patient with DD.
In 7 patients (18%) functional class could not be assessed because of
orthopedic problems. In the remaining 32 patients, there was noTable 1
Typical cardiac ﬁndings of various lysosomal storage disorders according to the literature.
LVH Diastolic dysfunction Valvu
MPS [7,19,31] +++ ++ ++
AFD [4,11,28,29,34] +++ ++ ++
PD [47] +++ +++ –
DD [24,25] +++ +++ –
ML II (ICD) [48] +++ ? +++
ML III [21] ? ? +++
Sphingolipidosis: Gaucher [49] + + +
MPS=mucopolysaccharidosis; AFD= Anderson Fabry disease; ML=mucolipidosis; ICD= I-
unknown.statistically signiﬁcant difference in NYHA classiﬁcation between the 3
groups.
3.2. Echocardiographic ﬁndings
A completely normal echocardiographic examwas present in 4 of 25
patients with MPS (16%), 7 of 8 patients with AFD (88%) and in the pa-
tient with M. Pompe (17% of oLSD). Echocardiographically detectable
changes are summarized in Tables 4 and 5. LV dilatation was rare and
LV hypertrophy was found in MPS patients (20%) and oLSD patients
(33%), but not inAFPpatients (p = 0.56). The patientwithDDhadmas-
sive left ventricular hypertrophy with a left ventricular muscle mass
index of 533 g/m2 (Fig. 1). All echocardiographic ﬁndings are shown
in Tables 4 and 5.
Signiﬁcant pulmonary hypertension was only seen in MPS (2/9,
22%). None of AFD and oLSD had non-invasively measured signiﬁcantly
elevated pulmonary artery pressures except for the patient with DD,
who had an additional intracavitary pressure gradient in the right ven-
tricle. There was no signiﬁcant difference in the presence of diastolic
dysfunction between the groups.
Valvular heart diseasewas frequent inMPS (76%) and oLSD (67%) as
shown in Table 5. There was no difference between the presence of mi-
tral or aortic valvular heart disease. In MPS, mitral valve (p = 0.001)
and aortic valve abnormalities (p = 0.006) were signiﬁcantly more
commonly seen than in oLSD or in AFD.
Figs. 2 and 3 show typical mitral valve abnormalities in a 18 years
old woman with MPS I and a 14 years old boy with MPS II.
3.3. ECG ﬁndings
An ECG was available in 36 of 39 patients. The ﬁndings are summa-
rized in Table 6. There was no signiﬁcant difference in age at ECG, heart
rate, PR interval, QRS duration and QTc duration or ventricular arrhyth-
mias between the groups (p = ns). There were no patients withlar HD AV block Preexcitation VPCs/VTs or SCD PHT
++ – – ++
+ – + –
– short PR – +
– short PR +++ –
? – +++ ?
? – ? ?
? ? ? ?
cell disease; += rare, ++= common; +++= very common; –=not described; ? =
Table 3
Clinical characteristics of the patients.
All patients
N = 39
MPS
N = 25
AFD
N = 8
oLSD
N = 6
p value
Median age (y) 11.4
(2.0, 27.6)
11.5
(2.0, 19.5)
10.8
(6.2, 17.1)
8.6
(2.9, 27.6)
0.82
Median body 26.0 26.0 33.3 24.4 0.48
Weight (kg) (5.3, 73.4) (11.0, 58.0) (20.0, 73.4) (5.3, 60.3)
Female gender 22 (56%) 11 (44%) 7 (88%) 4 (67%) 0.09
Heart murmur 19 (49%) 13 (52%) 2 (25%) 4 (67%) 0.33
NYHA class I 28/32 (88%) 17/20 (85%) 7/7 (100%) 4/5 (80%) 0.59
NYHA class II
or higher
4/32 (13%) 3/20 (15%) 0 1/5 (20%) 0.59
Heart failure 4 (10%) 3 (12%) 0 1 (17%) 0.60
MPS =mucopolysaccharidosis; AFD= Anderson Fabry disease; oLSD= other lysosomal
storage disease.
Table 5
Echocardiographic ﬁndings in valvular heart disease.
All patients
N = 39
MPS
N = 25
AFD
N = 8
oLSD
N = 6
p value
Any VHD 23 (59%) 19 (76%) 0 4 (67%) b0.001
Abnormal MV 21 (54%) 17 (68%) 0 4 (67%) 0.001
≥Mild MS 4 (10%) 3 (12%) 0 1 (17%) 0.60
≥Mild MR 17 (44%) 13 (52%) 0 4 (67%) 0.02
Abnormal AV 19 (49%) 16 (64%) 0 3 (50%) 0.006
≥Mild AS 3 (8%) 3 (12%) 0 0 0.41
≥Mild AR 9 (23%) 7 (28%) 0 2 (33%) 0.26
Abnormal TV 3 (8%) 1 (4%) 0 2 (33%) 0.06
Abnormal PV 5 (13%) 3 (12%) 0 2 (33%) 0.15
MPS=mucopolysaccharidosis; AFD = Anderson Fabry disease; oLSD= other lysosomal
storage disease; VHD= valvular heart disease; MV=mitral valve; MS=mitral stenosis;
MR = mitral regurgitation; AV = aortic valve; AR = aortic regurgitation; AS = aortic
stenosis; TV = tricuspidal valve; PV = pulmonary valve.
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AV block in one MPS; no higher degree AV blockage was found in our
patient cohort. The patient with DD was diagnosed with a WPW syn-
drome. Other ECG parameters did not show any differences between
the groups.
3.4. Treatment
Enzyme replacement therapy (ERT), was used in 13 patients (33%)
suffering of MPS [9], AFD [3] or PD [1]. Bone marrow transplantation
(BMT) was used in 6 patients (15%) with MPS I. There was no speciﬁc
therapy for patients with ML or DD. No patient was under cardiac
medication.
A summary of treatment for the LSD in these patients and the follow-
up information is shown in Table 7.
3.5. Follow-up
Median time of clinical follow-up after the ﬁrst contact with the
Children's University Hospital was 5.8 years (up to 22.2 years). Eight
patients (21%) died during the follow-up period. Three deaths of the
oLSD (50%) group had a diagnosis of ML II (2 deaths) and DD. One of
each MPS group I, II, III, IIIa and VI died (5/24 (21%) patients with a reg-
ular follow-up). The patient with MPS I was under ERT. Although ven-
tricular dilatation and/or abnormal function were present in 3 of the
patients who died subsequently, none of them died directly from
heart failure or sudden cardiac death. Causes of death were respiratory
failure in 7 patients and septicemia in one patient. 30 patients (79%)
were alive at the end of the follow-up period, including all patients
who had undergone BMT and all patients of the AFD group. All ﬁndingsTable 4
Echocardiographic ﬁndings.
All patients N = 39 MPS N = 2
Normal echo 12 (31%) 4 (16%)
Mean LVEDD (mm) 38.5 ± 6.7 37.7 ± 5.7
LV dilatation 6 (15%) 3 (12%)
Mean EF (%) 58.0 ± 7.2 59.2 ± 4.2
Median 68.8 70.6
LVMMI (g/m2) (31.1, 533.0) (31.1, 117.
LVH 7 (18%) 5 (20%)
Mean LA size (mm) 25.0 ± 5.1 24.7 ± 4.1
LA dilatation 8 (21%) 5 (20%)
Mean dp 20.4 ± 7.0 22.9 ± 9.0
RV/RA (n = 18) (n = 9)
PHT dpRV/RA N25 mm Hg 2/18 (11%) 2/9 (22%)
Diastolic dysfunction 5/24 (21%) 4/13 (31%)
MPS =mucopolysaccharidosis; AFD = Anderson Fabry disease; oLSD= other lysosomal stora
ejection fraction; LVMMI = left ventricular muscle mass index; LVH= left ventricular hypertrabout therapy and outcome are listed in Table 6. Five-year survival was
92% for MPS-, 100% for AFD- and 67% for oLSD-patients; there was no
statistical signiﬁcant difference between the groups (Fig. 4).
4. Discussion
Cardiovascular changes are frequently found in a pediatric popula-
tion with LSD. In our cohort only 31% of the patients had completely
normal cardiac ﬁndings. A heart murmur (49%) and valvular heart dis-
ease (59%)mostly ofmild degreewere themost common abnormalities
observed and they were almost exclusively conﬁned to children with
MPS and oLSD and not yet observed in children with AFD; this may be
due to the rather young age and/or higher number of females in our
AFD-group. Left ventricular hypertrophy and higher degree AV block
were rare in this age group in all types of LSD.
Cardiac symptoms in this age group were rare. Despite signiﬁcantly
decreased survival, thiswas not due to cardiac disease and cardiac inter-
ventions were not necessary in any of these children and adolescents
with MPS.
4.1. Differences in valvular heart disease between the lysosomal storage
disorders
Valvular heart disease in LSD has beenmost commonly described in
MPS, AFD, ML II and ML III (see Table 1). In our patients, we observed
valvular heart disease in 76% of patients with MPS, in 67% of those
with oLSD and in none of the patientswith AFD. Theseﬁndings are com-
parable to the literature. In a study on 28patientswithMPS,mitral valve
thickening was described in 61% and aortic valve thickening in 36% [7].5 AFD N = 8 oLSD N = 6 p value
7 (88%) 1 (17%) 0.001
39.8 ± 3.9 40.3 ± 12.2 0.62
0 3 (50%) 0.56
57.5 ± 3.6 53.8 ± 16.1 0.47
62.1 78.5 0.19
1) (50.4, 80.1) (56.0, 533.0)
0 2 (33%) 0.30
25.1 ± 5.4 25.6 ± 7.7 0.91
0 3 (50%) 0.30
18.7 ± 3.1 16.3 ± 3.5 0.31
(n = 6) (n = 3)
0/6 0/5 0.49
1 (13%) 0/3 0.60
ge disease; LVEDD= left ventricular end-diastolic diameter; LV = left ventricular; EF =
ophy; LA = left atrial; PHT = pulmonary hypertension.
LA RA 
LV 
RV 
a
b
Fig. 1. 15-Year old patient with Danon disease: parasternal long axis view with massive
hypertrophy (panel a) measuring 39 mm. The 4-chamber view (Fig. 1b) shows the rela
tion to the size of the right ventricle. In panel c, the ECG of this patient is shown with
marked signs of left ventricular hypertrophy. LA = left atrium; LV = left ventricle
AO= aorta; RA = right atrium.
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cents by Kampmann et al. [16], no heart valve changes were described.
Heart valve changes in AFD can occur, they have been reported to occur
in 14.6% in a registry; however, they are rarely hemodynamically signif-
icant even in adults with advanced disease [17,18].
None of our patients needed valve surgery. In the literature, valve re-
placement has rarely been reported. In a group of children and young
adults (21 months to 25 years) withMPS, Dangel et al. described valvu-
lar lesions and/or cardiomyopathy in 72% of patients [19]. The lesions
were progressive but rarely led to cardiac symptoms. Only one boy
with Hunter disease had to undergo successful mitral valve replace-
ment. Both, aortic and mitral valve replacement was reported in a
14 year old female with Gaucher disease and mucolipidosis III [20,21].
Hopefully, in the current times of increasing options of enzyme replace-
ment therapy in LSD, valve replacement in these patients will become
even more rare.
4.2. Wall thickening of the left ventricle
Left ventricular wall thickening in AFD may mimic hypertrophic
non-obstructive or obstructive cardiomyopathy in an adult population
[22]. To our knowledge, however, obstructive hypertrophic cardiomy-
opathy due to AFD has not been described in children with AFD. In our
pediatric AFD patients no signiﬁcant left ventricular hypertrophy was
detected. In AFD, onset of left ventricular wall thickening is earlier in
males than females [23]. However, none of our male infants with AFD
had left ventricular hypertrophy. Left ventricular wall thickening mim-
icking left ventricular “hypertrophy” predominated in the MPS group
and oLSD. None of our patients with any LSD had a left ventricular out-
ﬂow tract gradient. Left ventricular wall thickening can also occur in
other LSD such as Danon disease and Pompe disease [24–26].
In our patients, the most impressive wall thickening was seen in the
patients with Danon disease who died during follow-up. Lysosome-
associated membrane protein-2 deﬁciency (LAMP-2 deﬁciency), also
called Danon disease, is a rare X-linked lysosomal disorder character-
ized by impressive cardiomyopathy, vacuolar myopathy, and mental
retardation. Danon disease may cause concentric left ventricular hyper-
trophy; in any male teenager with concentric LVH, especially in the
presence of elevated serum hepatic enzymes and CK concentrations,
and/or WPW syndrome with markedly increased voltage of the left
ventricle. Rarely, left ventricular outﬂow tract obstruction has been de-
scribed in Danon disease [27]. In patients with Danon disease timely
molecular diagnosis and early consideration of heart transplantation
are recommended [25].
4.3. Pulmonary hypertension
The etiology of pulmonary hypertension in patients with LSD ismul-
tifactorial: severe scoliosis, obstructive sleep apnea inMPS patients, and
diastolic dysfunction are themain causes. Pulmonary hypertension was
detected by echocardiography only in 2 patients, and it was not hemo-
dynamically signiﬁcant. In any patient withMPS and pulmonary hyper-
tension, one has to think of obstructive sleep apnea as in these patients,
partially degraded GAGs can accumulate also in the upper airways [27].
In our patients, sleep studies were not performed routinely.
4.4. Changes in AV conduction in lysosomal storage disorders
A short PR interval is considered typical of AFD and due to accelerat-
ed atrioventricular conduction; it is seen in 14 to 40% of patients [28,29].
Older patients with AFDmay develop bundle branch block and progres-
sive AV conduction abnormalities. In our patients, a short PR interval did
not only occur in patients with AFD (in 25%) but also in MPS (26%) and
oLSD (50%). Thus shortening of the PR interval is not speciﬁc for AFD.
Complete AV block can occur in MPS [30,31] and may even cause
sudden cardiac death in MPS as described by Hishitani et al. [31].In the past, the incidence of sudden death in patients with MPS was re-
ported to be as high as 11%, thus in these patients, careful surveillance
with Holter ECG is needed [32]. In one of our patients with MPS, there
was 2nd degree AV block in the 24 h-ECG during daily activities. This
patient died 19 years old due to respiratory infection. Complete AV
block in AFD has been described in middle-aged women [33], but to
our knowledge this is a rarity in children.
4.5. Impact of therapies
Nowadays, the clinical course ofmany childrenwith LSD is attenuat-
ed by treatments such as ERT and BMT in MPS I; the long-term effect of
which has yet to be determined. Among our patients, 6 of 7 (85%) with
MPS I (Hunter) had BMT, all 7 patients with MPS I were alive at the last
follow- up.-
;
Fig. 1 (continued).
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3 MPS VI, one PD). One 9 years old girl withMPS VI died due to respira-
tory failure and progressive hypoventilation subsequent to
craniocervical compression myelopathy despite treatment with ERT.
The safety and effectiveness of ERT for AFD, MPS I, MPS II and MPS VI,
as well as for PD have been demonstrated in well-designed clinical tri-
als, and the treatments are now commercially available throughoutLA 
LV
RV
Fig. 2. Example of an 18-year old woman with mucopolysaccharidosis. This shows the
apical 4-chamber view (apex down) with the arrow pointing to the thickened mitral
valve. No progression or regression of valvular changes after 2 years of enzyme replace-
ment therapy was observed. LA = left atrium; LV = left ventricle; RV = right ventricle.the world [34–45]. However, except for PD (Invasive ventilator-free
survival, changes in LVMI) efﬁcacy end points did not include cardiac
function. The heart is one of the major organs affected in patients with
AFD, almost allmale patientswith classic AFDwill develop hypertrophic
cardiomyopathy if untreated. Thus cardiac disorders including con-
duction disturbances, valve disease and heart failure have been well
documented; ERT results in a dramatic improvement in cardiac symp-
toms in a substantial number of patients [46]. To further assess objective
cardiac beneﬁts including reduction of cardiovascular morbidity and
mortality in MPS disorders, data from large registries will be of utmost
importance, due to the rarity of the individual disorders.
Thus many of these patients will hopefully reach adulthood under-
lining the necessity that adult cardiologists are also getting familiar
with these rare diseases, although we recommend that most of these
patients are followed-up in specialized centers.Fig. 3. 14-Year old patient with mucopolysaccharidosis Type II (hunter disease). LA= left
atrium; LV = left ventricle.
Table 6
ECG ﬁndings.
All patients N = 36 MPS N = 23 AFD N = 8 oLSD N = 5 p value
Age (median) 10.9 (0.3, 28.3) 11.2 (2.1, 20.0) 11.1 (6.3, 17.5) 4.8 (0.3, 28.3) 0.82
Heart rate, mean (bpm) 87.9 ± 25.2 88.9 ± 21.5 77.0 ± 9.1 100.6 ± 49.0 0.27
PR interval, mean (ms) 134.2 ± 42.3 141.2 ± 48.4 125.8 ± 18.8 110.5 ± 31.0 0.34
PR interval b120 ms 10/35 (29%) 6 (26%) 2 (25%) 2/4 (50%) 0.73
QRS duration, median (ms) 81 (56, 170) 82 (64, 108) 79 (76, 86) 84 (56, 170) 0.76
Median QTc duration (ms) 423 (380, 489) 425 (380, 452) 409 (398, 432) 432 (405, 489) 0.14
Mean QRS axis (°) 68.0 ± 32.2 71.4 ± 37.6 63.6 ± 14.8 59.2 ± 27.3 0.39
Preexcitation 1 (3%) 0 0 1 (20%) 0.14
24 h-ECG 12/39 (31%) 4/25 (16%) 6/8 (75%) 2/6 (33%) 0.006
Isolated PVC's 7/12 (58%) 1/4 (25%) 5/6 (83%) 1/2 (50%) 0.42
AF 1/12 (8%) 0/4 0/6 1/2 (50%) 0.17
2nd AVB 1/12 (8%) 1/4 (25%) 0/6 0/2 0.50
MPS=mucopolysaccharidosis; AFD=Anderson Fabry disease; oLSD= other lysosomal storage disease; PVC's= premature ventricular contraction; AF= atrial ﬁbrillation; 2nd AVB=
second degree AV-block.
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In our patient group, follow-up time was limited and averaged only
5.8 years. However,manypatientswith LSD die prematurely and donot
reach adulthood, which explains part of the short follow-up. In our
study, 8 patients died, one was lost to follow-up.
Unfortunately, detailed analysis of diastolic function is not available
in all patients, most often due to a fast heart rate or diminished echo
quality due to body habitus. Also, nodetailed analysiswithmodern tech-
niques (speckle tracking) has been performed routinely in older studies.
LSD is a rare disease. So, although these children and adolescents are
all patients of a tertiary referral center, this is still a small group. Thus,
comparisons between the groups are difﬁcult to interpret.Table 7
Treatment and outcome.
All patients
N = 39
MPS
N = 25
AFD
N = 8
oLSD
N = 6
p value
BMT 6 (15%) 6 (24%) – – 0.18
ERT 13 (33%) 9 (36%) 3 (38%) 1 (17%) 0.78
No therapy 22 (56%) 12 (48%) 5 (63%) 5 (83%) 0.26
Death 8/38 (21%) 5/24 (21%) 0 (0%) 3 (33%) 0.28*
Mean age death (y) 12.0 ± 6.1 14.2 ± 5.2 – 8.3 ± 6.6 0.10
MPS =mucopolysaccharidosis; AFD= Anderson Fabry disease; oLSD= other lysosomal
storage disease; BMT = bone marrow transplantation; ERT = enzyme replacement
therapy; * log-rank test.
AFP
MPS
oLSD
normal population
Fig. 4.Kaplan–Meier curve of the survival of theMPS, AFD and oLSDpatients compared to an
age and sex matched white American normal population. MPS =mucopolysaccharidosis;
AFD = Anderson Fabry disease; oLSD= other lysosomal storage disease.We do not have data on polysomnography in all patients with
pulmonary hypertension. Therefore, the exact etiology of pulmonary
hypertension cannot be determined.
5. Conclusions
Echocardiographically detectable cardiovascular involvement is fre-
quent in children with LSD. However, cardiovascular ﬁndings are rarely
hemodynamically signiﬁcant and mostly do not necessitate any inter-
vention. Valvular heart disease occurs mainly in patients with MPS
and oLSD but is rare in AFD. A short PR interval is a characteristic ECG
abnormality. Routine repeat evaluation with echocardiography and
ECG is recommended in children with LSD.
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